Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole

British Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2009, Pages 712-720

  Grün, Barbara ^a   Krautter, Stefanie ^a   Riedel, Klaus Dieter ^a   Mikus, Gerd ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Cyp2c19; Cyp3a4; Inhibition; Metabolism; Nortilidine; Tilidine

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DINORTILIDINE; NORTILIDINE; PLACEBO; TILIDINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VALORON N; VORICONAZOLE;

ADULT; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HEADACHE; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PAIN; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER; VOMITING;

ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; TILIDINE; TRIAZOLES; YOUNG ADULT;

EID: 70449419843     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03498.x     Document Type: Article

References (25)

1. International Narcotics Control Board. Narcotic Drugs: Estimated World Requirements for 2007 and Statistics for 2005 (E/INCB/2006/2). New York : United Nations, 2007.
2. Nikolaus T, Zeyfang A. Pharmacological treatments for persistent non-malignant pain in older persons. Drugs Aging 2004 21 : 19 41.
3. Flöter T, Brunnmuller U. Tilidine/naloxon retard in long-term administration in chronic pain and multimorbidity. Multicenter study of long-term tolerance and effectiveness in 2 years observation. Fortschr Med Orig 2002 120 : 29 35.
4. Wörz R, Wörz E. Long-term treatment of chronic pain with tilidine-naloxone. An analysis of 50 patients with chronic pain conditions of non-malignant origin. Fortschr Med 1995 113 : 388 392.
5. Vollmer KO, Thomann P, Hengy H. Pharmacokinetics of tilidine and metabolites in man. Arzneimittelforschung 1989 39 : 1283 1288.
6. Thierry C, Boeynaems JM, Paolo M. Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol 2005 506 : 205 208.
7. Hajda JP, Jähnchen E, Oie S, Trenk D. Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine. J Clin Pharmacol 2002 42 : 1257 1261.
8. Seiler KU, Jähnchen E, Trenk D, Brennscheidt U, Heintz B. Pharmacokinetics of tilidine in terminal renal failure. J Clin Pharmacol 2001 41 : 79 84.
9. Weiss J, Sawa E, Riedel K-D, Haefeli WE, Mikus G. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Pharmacol 2008 378 : 275 282.
10. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003 56 : 10 6.
11. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003 31 : 540 547.
12. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006 79 : 362 370.
13. Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008 64 : 25 30.
14. FDA Antiviral Drugs Advisory Committtee. Briefing Document for Voriconazole (Oral and Intravenous Formulations). 4 October 2001. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2-02-FDA-voriconazole.pdf (last accessed 15 June 2009).
15. Jones SF, McQuay HJ, Moore RA, Hand CW. Morphine and ibuprofen compared using the cold pressor test. Pain 1988 34 : 117 122.
16. Garcia de Jalon PD, Harrison FJ, Johnson KI, Kozma C, Schnelle K. A modified cold stimulation technique for the evaluation of analgesic activity in human volunteers. Pain 1985 22 : 183 189.
17. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998 76 : 27 33.
18. Blasco T, Bayes R. Unreliability of the Cold Pressor Test Method in pain studies. Methods Find Exp Clin Pharmacol 1988 10 : 767 772.
19. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000 17 : 1551 1557.
20. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 1998 64 : 391 401.
21. Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006 79 : 103 113.
22. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg MA, Eliasson E, Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008 65 : 767 774.
23. Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009 49 : 196 204.
24. Handal KA, Schauben JL, Salamone F. Naloxone. Ann Emerg Med 1983 12 : 438 445.
25. Albeck H, Woodfield S, Kreek MJ. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J Chromatogr 1989 488 : 435 445.